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Epidemic aluminum intoxication in hemodialysis patients traced to use
of an aluminum pump. This study was designed to identify the source, risk
factors, and clinical consequences of an outbreak of aluminum intoxica-
tion in hemodialysis patients using case-control and cohort studies, In
1991, a dialysis center in Pennsylvania [Dialysis Center A (DCA)]
identified a number of patients with elevated serum aluminum levels. All
patients receiving dialysis at DCA during Januaiy 1, 1987 to March 26,
1992 were involved in the study. A case-patient was defined as any patient
with a serum aluminum level 100 sgIliter after dialysis sessions at
DCA. Fifty-nine case-patients were identified. Risk factors for elevated
serum aluminum levels were receipt of bicarbonate- (rather than acetate-)
based dialysate, higher number of sessions using bicarbonate dialysis,
receipt of acid concentrate (used in bicarbonate dialysis) passed through
one of two electric pumps, and a greater number of sessions using this
concentrate. The electric pumps had an aluminum casing, casing cover,
and impeller. Elevated levels of aluminum were found in acid concentrate
after passing through a pump. Seizures and mental status changes
requiring hospitalization were associated with aluminum exposure. We
found that epidemic aluminum intoxication was caused by the use of an
electric pump with aluminum housing to deliver acid concentrate used in
bicarbonate dialysis. This outbreak demonstrates why it is essential to
insure that all fluid pathways, storage tanks, central delivery systems, and
pumps are compatible with low pH fluids before converting from acetate
to bicarbonate dialysis.
Aluminum intoxication can cause dialysis encephalopathy, also
called dialysis dementia [1], a demineralizing osteodystrophy [2],
and anemia [3]. The two severe manifestations, dialysis encepha-
lopathy and fracturing osteodystrophy, were reported as epidemic
occurrences in hemodialysis centers worldwide from the late
1960's through the early 1980's [4—20]. The source of these
outbreaks was usually parenteral exposure to high concentrations
of aluminum in water used in dialysate in areas where alum or
aluminum sulfate was added as a flocculent to municipal water
supplies. To address this problem, water treatment with reverse
osmosis units or deionizers was shown to remove aluminum and
other harmful chemicals [12, 13, 17, 18], and the Association for
the Advancement of Medical Instrumentation (AAMI) published
standards for maximum aluminum levels in water used in dialysate
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in 1981 [21]. Two other sources of epidemic aluminum intoxica-
tion in dialysis patients have been reported: a boiler aluminum
anode that contaminated water used in dialysate [22], and an
aluminum-containing cartridge used in a sorbent regeneration
system, which disintegrated and contaminated the dialysate [23].
Currently, although aluminum intoxication in renal failure
patients occurs sporadically due to oral aluminum-containing
medications [24—28], reports of the epidemic occurrence of
aluminum intoxication in dialysis centers, with associated severe
clinical manifestations, have virtually disappeared.
However, in 1991, a dialysis center in Pennsylvania [Dialysis
Center A (DCA)], identified a number of patients with elevated
serum aluminum levels. In 1988, structural renovations and the
installation of electric pumps to deliver concentrates used in
dialysate from the ground floor to the second floor had occurred.
From 1988 through 1992, bicarbonate dialysis use had increased.
When the initial investigation suggested contaminated dialysate,
DCA discontinued use of the delivery system, and the Centers for
Disease Control and Prevention (CDC) and the Food and Drug
Administration were notified and assisted in the investigation.
Methods
Identification of patients with elevated serum aluminum levels
To identify patients with elevated serum aluminum levels, we
reviewed medical records of all DCA patients present during
January 1, 1987 to March 26, 1992 (study period). Most patients
had at least one, and commonly had quarterly, aluminum levels.
Monthly aluminum testing was started in January 1992.
Case/noncase definitions
Next, we defined a case-patient as any patient during the study
period with a serum aluminum level  100 .rg/liter (normal 0 to
12) after 5 dialysis sessions at DCA. Aluminum levels measured
after administration of deferoxamine, which can increase serum
aluminum levels, were excluded. We defined a control or noncase-
patient as any patient during the study period with a maximum
serum aluminum level <100 pg/liter after 5 dialysis sessions at
DCA.
Analysis of risk factors for elevated aluminum levels
Since the majority of case-patients had elevated aluminum
levels after October 15, 1988, the approximate date of installation
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Fig. 1. Distribution of patients with semm aluminum level 100pg/liter by month, DCA, January 1, 1987 to March 26, 1992. Sixty-four patients had a serum
aluminum level 100 pg/liter during the study period; one patient with first aluminum level pg/liter before 1987 is not shown. In January 1992,
a large number of patients with a serum aluminum level 100 gg/liter were identified due to a point prevalence survey. At A, two electric pumps were
installed at DCA, approximately October 15, 1988; at B, acid concentrate was initiated through one pump, January 1, 1990; at C, acid concentrate was
initiated through the second pump, February 1, 1992; at D, use of both pumps was discontinued, February 7, 1992.
of the electric pumps, the epidemic period was defined as October
15, 1988 to February 7, 1992. To determine risk factors for
elevated aluminum levels during the epidemic period we ran-
domly selected and compared 10 of the case- and 10 control-
patients. Because one of the identified risk factors was not present
until after December 31, 1989, we next performed a cohort study
of all DCA patients receiving dialysis during January 1, 1990 to
February 7, 1992, for a total of 102 (including 17 case-control
study) patients. Twelve patients who did not have an aluminum
level after January 1, 1990 and four who had a level but not after
5 dialysis sessions were excluded; most were only transiently
dialyzed at DCA (<2 months). Risk factors evaluated included
demographic factors, receipt of medications containing alumi-
num, and type of dialysate, dialyzer, and dialysis machine used.
Dialysis sessions included were from the beginning of the period
being evaluated (that is, October 15, 1988 for the case-control
study or January 1, 1990 for the cohort study) until the date of the
patient's subsequent maximum aluminum level, before deferox-
amine.
Procedural investigation
Laboratory investigation of environmental samples
Samples of acetate and bicarbonate dialysate, and acid, bicar-
bonate and acetate concentrate were collected for determination
of aluminum levels. Aluminum assays were performed at Damon
Clinical Laboratories, Inc. (Smyrna, GA, USA) or Serco Labora-
tories (St. Paul, MN, USA) using the atomic absorption method
[29, 30]. One DCA electric pump was sent to CDC for examina-
tion and testing; acid concentrate was passed through the pump
and tested for aluminum.
Laboratory investigation of autopsy specimens
Fresh autopsy specimens of brain from one patient suspected of
having aluminum intoxication were sent to National Medical
Services, Inc. (Willow Grove, PA, USA) for aluminum testing.
We reviewed the design and maintenance of DCA dialysate
delivery and water treatment systems and water quality monitor-
ing records.
1 Use of company or trade names is for identification only and does not
imply endorsement by the Public Health Service or the U.S. Department
of Health and Human Services.
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Analysis of clinical characteristics of patients with
aluminum exposure
To determine the clinical characteristics of patients in the
cohort study, we reviewed their outpatient and/or inpatient med-
ical records. Data were collected on mental status change requir-
ing hospitalization, seizures (generalized tonic-clonic convulsions
requiring hospitalization, partial seizures, or epileptiform activity
on electroencephalogram leading to anticonvulsant treatment),
bone fractures, and receipt of blood transfusions, erythropoietin,
iron dextran injections, or deferoxamine. Potential associations of
selected clinical characteristics with aluminum exposure (before
onset) were evaluated. Based on our initial investigation, a dialysis
session using acid concentrate pumped through the electric
pumps was defined as an aluminum exposure. Seizures or mental
status change of clear etiology unrelated to aluminum (such as
hypernatremia, sepsis) were not defined as a positive outcome in
the analysis.
Patients with aluminum exposure were given deferoxamine
stimulation tests and treated when appropriate with intravenous
0.5 to 1 g deferoxamine, usually administered weekly, until
stimulated serum aluminum levels were similar to unstimulated
levels. Patients present at DCA after February 7, 1992 were
followed for one year.
Statistical methods
Data were entered into a microcomputer and analyzed using
Epi Info [311. The Fisher's exact or test was used for analysis of
categorical variables; the Kruskal-Wallis test was used for analysis
of continuous variables. To assess the relationship between two
variables, we calculated a Pearson's correlation coefficient by
linear regression analysis.
Results
During the study period, 64 patients had a serum aluminum
level 100 jig/liter; many were identified in January 1992 due to
testing of all patients (Fig. 1). Thirteen of these had levels as high
as 300 to 500 jig/liter; six had levels >500 jig/liter.
The proportion of patients with serum aluminum levels 100
jig/liter was higher during the period after the electric pumps were
installed (October 15, 1988 to March 26, 1992) than before they
were installed (January 1, 1987 to October 14, 1988); 60 of 133
(45%) versus 3 of 86 (3.5%), relative risk (RR) of 13, and P
<0.0001 (analysis excludes one patient with a first serum alumi-
num level 100 jig/liter before the study period). Fifty-nine
(92%) of the 64 patients with serum aluminum levels  100
jig/liter met the case definition.
Analysis of risk factors for elevated aluminum levels
Case-control study. Case-patients were significantly more likely
than controls to have a higher number of dialysis sessions using
bicarbonate dialysis (median 101 vs. 0, P = 0.01), higher number
of sessions using acid concentrate (used in bicarbonate dialysis)
passed through an electric pump (37.5 vs. 0, P = 0.02), or higher
number of sessions using COBE Centrysystem 2 (COBE Labora-
tories, Inc., Lakewood, CO, USA) dialysis machines (12.5 vs. 0, P
= 0.01).
Cohort study. Of 86 DCA patients included in the cohort study,
59 met the case definition. Risk factors were all those identified in
the case-control study plus higher number of dialysis sessions,
Table 1. Comparison of potential risk factors among patients with a
serum aluminum level 100 jrg/liter' (case-patients) versus patients
with maximum serum aluminum level <boa jig/liter (noncase-patients),
from Dialysis Center A, January 1, 1990—February 7, 1992
Continuous van ables [medians (25th, 75th percentiles)]
Potential risk Cases Noncases
factors (N = 59) (N = 27) P value
Number of dialysis 93 (44, 159) 34 (16, 118) 0.007
sessions
Number of dialysis
sessions using
COBE machine 6 (1, 20) 0 (0, 7) 0.0 12
SPS45O machine 69 (41, 129) 28 (6, 99) 0.010
Bicarbonate 77 (35, 125) 0 (0, 18) <0.0001
dialysate
Acid concentrate 45 (15, 84) 0 (0, 3) <0.0001
through
electric pump
Acetate dialysate 0 (0, 9) 16 (0, 87) 0.013
Acetate 0 (0, 9) 16 (0, 87) 0.013
concentrate
through
electric pump
Potential risk factors
Categorical variables
Rate RRb 95% CF P value
Predominant machine
SPS45O 52/73 (71%) 1.32 0.78—2.23 0.33
CUBE 7/13 (54%)
Predominant bath
Bicarbonate dialysate
Acetate dialysated
51/61 (84%) 2.61 1.46—4.68
8/25 (32%)
<0.0001
Acid concentrate
through electric
pump
Yes 52/62 (84%) 2.88 1.53—5.42 <0.0001
No 7/24 (29%)
Acetate concentrate
through electric
pump
Yes 22/40 (55%) 0.68 0.50—0.94 0.021
No 37/46 (80%)
Serum aluminum level
before 1/1/90
>100 jig/liter
Yes 8/8 (100%) 1.53 1.30—1.80 0.052
No 51/78 (65%)
a Before receipt of deferoxamine
bRelative risk
95% confidence interval
dAcetate dialysis sessions  bicarbonate dialysis sessions
higher number of sessions using SPS45O (Baxter Healthcare
Corporation, Largo, FL, USA) dialysis machines, receipt of
predominantly bicarbonate dialysate, and receipt of acid concen-
trate passed through an electric pump (Table 1). Age, gender,
duration of dialysis at DCA, type of dialyzer, use of predominantly
CUBE or SPS45O machines, or receipt of oral medications
containing aluminum or citrate were not associated with becom-
ing a case-patient. Receipt of acetate concentrate through an
electric pump, higher number of sessions using acetate dialysate,
and higher number of sessions using acetate concentrate through
an electric pump were protective factors.
We controlled for the number of dialysis sessions by examining
exposures only during the month before the maximum aluminum
472 Burwen et a!: Epidemic aluminum intoxication
City water
Reverse osmosis
product water
Acid concentrate
Acid concentrate
Acid concentrate
Used with SPS45O machines
bUsed with COBE machines
Aluminum pumps removed 2/21/92
storage tank 1a
storage tank 1, and after
passing through the
aluminum pump
storage tank 1, and after
passing through the
aluminum pump
storage tank 2b and after
passing through the
aluminum pump
storage tank 1, and after
passing through plastic
pumpc
storage tank 2, and after
passing through plastic
pump
before entering machine
before passing through
dialyzer
level. Exposure to bicarbonate dialysis (55 of 67 vs. 4 of 19, RR =
3.9,P < 0.0001) or acid concentrate through an electric pump (48
of 56 vs. 11 of 30, RR = 2.3, P < 0.0001) were significant; acetate
dialysate (3 of 20 vs. 56 of 66, RR = 0.18, P < 0.0001) and acetate
concentrate through an electric pump (3 of 20 vs. 56 of 66, RR =
0.18, P < 0.0001) were again protective factors. The type of
dialysis machine was not significant.
When we stratified by receipt of acid concentrate through an
electric pump, receipt of predominantly bicarbonate dialysis or
use of predominantly COBE or SPS45O machines were not
significant.
The maximum serum aluminum level (before deferoxamine)
and number of dialysis sessions using acid concentrate through an
electric pump were positively correlated (r 0.63).
Environmental and procedural investigation
Before October 1988, acetate or acid concentrate was stored in
55 gallon drums and extracted using a hand pump. In October
1988, two 500-gallon storage tanks were introduced, which were
located at ground level. Two electric pumps (Teel Industrial
Series model 1P862, Dayton Electric Manufacturing Company,
Chicago, IL, USA) were installed to pump fluid from the tanks to
the second floor of DCA, via polyvinylchloride and vinyl pipes.
From October 1988 through December 1989, both storage tanks
contained acetate concentrate. In January 1990, because an
increasing number of patients were being treated with bicarbonate
dialysate, one tank was converted to acid concentrate for use with
SPS45O dialysis machines. On February 1, 1992, the second tank
was coaverted to acid concentrate, for use with COBE machines.
Laboratory investigation of autopsy specimens
Autopsy specimens of brain from one patient with encephalop-
athy had an elevated level of aluminum in the gray matter
compared to that in the white matter; 8.2 and 2.0 pg/gm wet wt,
respectively. This patient had 172 dialysis sessions of aluminum
exposure and a maximum serum aluminum level of 642 jLg/liter.
Analysis of clinical characteristics of patients with
aluminum exposure
Patients in the cohort study had 0 to 181 (median 50) dialysis
sessions with aluminum exposure. Seventeen (20%) had hospital-
i.zations for mental status change or seizures. These patients had
significantly more dialysis sessions with aluminum exposure than
did patients without these problems (mental status change: me-
dian 92.5 vs. 40.5, P 0.0006; seizure: 109.5 vs. 45.5, P = 0.002).
Nine of the 17 patients had neurologic or systemic diseases
unrelated to aluminum intoxication which could affect their
mental status, such as cerebrovascular disease, pre-existing sei-
zure disorder (previously controlled), amyloidosis, or pneumonia.
Characteristics of the eight patients without identifiable pre-
existing neurologic problems included seizures in 5 (63%), en-
cephalopathy in 4 (50%), myoclonic jerks in 3 (38%), speech
difficulty in 6 (75%), inappropriate behavior in 3 (38%), halluci-
nations in 2 (25%), dementia in 1 (13%), confusion in 7 (86%),
disorientation in 6 (75%), and lethargy in 4 (65%). Clinical
characteristics of the two groups did not differ significantly.
Fifteen (88%) of the 17 patients with hospitalizations for mental
status change or seizures had onset before or within a few days
after February 7, 1992, when use of the aluminum pumps was
Table 2. Dialysis fluid aluminum assays, Dialysis Center A
Specimen Source
Date of
collection
2/12/92 Acid concentrate
2/12/92 Acid concentrate
2/18/92 Acid concentrate
2/18/92 Acid concentrate
4/21/92 Acid concentrate
4/21/92 Acid concentrate
Bicarbonate solution
Bicarbonate dialysate
4/21/92
4/21/92
4/21/92
4/21/92
5/1/92
5/1/92
5/1/92
On February 7, 1992, DCA discontinued use of the electric
Aluminum pumps. On February 18, the storage tanks were emptied and
mg/liter cleaned; they were then refilled. On February 20, the electric
pumps were removed and replaced with plastic electric pumps
302 (model MDX-MT3, March Manufacturing, Inc., Glenview, IL,
USA). Each of the removed pumps had an aluminum casing,
casing cover, and impeller.
2.9 The water treatment system included a reverse osmosis unit and
a back-up deionization unit. Routine testing of the treated water
0.05 1 (product water) for aluminum was performed once in 1987 and
approximately every six months during February 1989 to February
1992; results always met AAMI standards [21, 29].
0.007
Laboratory investigation
<0.005 Product water samples obtained in April 1992 during our
investigation had aluminum levels within AAMI standards. Alu-
0.029 minum levels in acid or acetate concentrate, bicarbonate solution,
<o.oos or dialysate were also low (Table 2). Acid concentrate samples
collected in February 1992 after passing through the aluminum
0.018 pump had variable aluminum levels depending upon the date of
<0.005 collection, but all levels were elevated. Based on the 302 and 2.9
<0.005 mg/liter measurements, the calculated aluminum level in dialysate
200 after 1:36 dilution by the SPS45O dialysis machine is 81 to 8400
xgIliter. This value is 8.1 to 840 times the maximum AAMI
870 recommended aluminum level in product water. When the DCA
pump was set up at CDC, acid concentrate passed once through
the pump, or left in the pump over a weekend and then flushed,
had high levels of aluminum. The pH of selected acid concentrate
samples was 2.6 and for acetate concentrate was 6.7.
CDC
CDC; single pass through
aluminum pump
CDC; after 3 days in
aluminum pump
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discontinued. The other two patients had onset two months after
this date. Bone fractures, or receipt of blood transfusions, eryth-
ropoietin or iron dextran injection were not associated with
aluminum exposure.
Discussion
Epidemic aluminum intoxication occurred in DCA in associa-
tion with the increased use of bicarbonate dialysis and the delivery
of acid concentrate through an aluminum pump. Unlike previ-
ously reported epidemics, this outbreak occurred while an effec-
tive water treatment system was in place, and was due instead to
a device used in the dialysate delivery system. The potential for
similar epidemics may be increased because the percentage of
U.S. dialysis centers using bicarbonate-based dialysate as their
primary method of dialysis has increased from 22% in 1986 to
92% in 1991 [32].
The two aluminum pumps installed at DCA in October 1988
were initially used to deliver acetate concentrate, which has a
neutral pH. Subsequently, acid concentrate for 5P5450 machines
was delivered through one aluminum pump during January 1990
to February 1992. Acid concentrate was used with the second
aluminum pump only during a one week period in February 1992.
Evidence implicating the aluminum pumps, and specifically the
delivery of acid concentrate through one pump over a two year
period includes the strong epidemiologic associations with receipt
of acid concentrate through a pump, receipt of bicarbonate
dialysate, higher number of sessions using 5P5450 machines, and
the correlation between serum aluminum level and higher number
of sessions with acid concentrate through a pump which suggests
a dose-response. Laboratory results showing high levels of alumi-
num in acid concentrate which had passed through one pump and
low levels in DCA samples taken after the pump was removed
confirmed the aluminum-containing pump as the source of chem-
ical contamination.
Factors contributing to the perpetuation of the outbreak over a
two year period included case-patients being distributed among
physician groups so individual physicians were not aware of the
extent of the outbreak, variability in patients' serum aluminum
levels causing confusion about their clinical significance, and
receipt of oral aluminum phosphate binders by some patients who
seemed therefore to have a plausible cause for their elevated
serum aluminum level. Discontinuation of aluminum containing
medications was often done concomitantly with a change in
patients' dialysate to a low calcium bath. Aluminum levels im-
proved, reinforcing the belief that discontinuation of these med-
ications controlled the problem; however, in retrospect, the
improvement was probably mainly due to the new bath which did
not use acid concentrate through the aluminum pump.
Results of aluminum testing of autopsy specimens of brain
tissue available from one patient were consistent with aluminum
encephalopathy [33—36]. Although similar data are not available
for other patients, the epidemiologic association of seizures or
mental status change with aluminum exposure supports our belief
that the neurologic problems of a number of other patients were
due to aluminum intoxication. In eight patients, these manifesta-
tions had no clear etiology and in retrospect may have been due
to aluminum intoxication. Another nine patients had concomitant
neurologic or systemic diseases that may have either solely
accounted for their subsequent abnormalities or predisposed
them to clinical manifestations of aluminum intoxication.
Persons involved in the operation of dialysis centers should be
aware of the potential for contamination of dialysate or water by
aluminum or other chemicals. Flouride, chloramine, sulfate,
nitrate, zinc, sodium azide, and copper can cause toxicity in
dialysis patients, and many other chemicals pose a potential
hazard [21, 29, 37—39]. Materials used in water treatment and
dialysate delivery systems, including fluid pathways, storage tanks,
central delivery systems, and pumps, should be compatible with all
fluids in the system [21, 29, 37]. Modifications of the water
treatment, dialysate delivery, or dialyzer reprocessing systems
should only be made by personnel knowledgable about these
systems and AAMI standards for water and dialysate used in
hemodialysis. Based on this outbreak, the Food and Drug Admin-
istration sent a Safety Alert to U.S. dialysis centers recommending
reassessment of the design of and components used in the water
treatment, concentrate delivery transfer/storage, and dialysate
delivery systems whenever changing or updating any component
of an existing dialysis unit, and routine monitoring of serum
aluminum levels in dialysis patients [40].
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